Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback